Elisabeth Letellier, PhD, of Luxembourg City, Luxembourg-based University of Luxembourg, and colleagues used meta-analyzed gene expression data to study how different members of the Myosin V family expressed themselves in CRC patients.
Researchers used laser-microdissected materials and tissue microarrays paired with human CRC samples to validate RNA and protein expression of Myosin Vb as well as known adapter proteins in patients.
Researchers discovered methylation-independent loss of MYO5B expression in CRC patients matched disease progression. Although a number of disease mutations were identified in a small patient group, researchers don’t feel the mutations were solely responsible for the downregulation in CRC patients.
Researchers determined CRC patients with lower MYO5B expression had shorter overall disease and metastasis-free survival as compared to those with normal expression.
They concluded, “Our data identify MYO5B as a powerful prognostic biomarker in CRC, especially in early stages (stages I and II), which might help stratifying patients with stage II for adjuvant chemotherapy.”
More articles on gastroenterology:
Southwest Ohio Gastroenterology sold & more: 3 GI practices in the news
AGA enrolls 1st patient into largest planned fecal microbiota transplantation study
Weill Cornell researchers identify cells responsible for immune response in gut — 4 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
